Company Profile
Equillium, Inc. Stock Price, News & Catalysts
- Ticker:
- EQ
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.89 USD (+1.89%)
Close
Last updated: September 17, 2026
176M USD
Market cap
Why the stock is moving
Following the latest company update, “Equillium to Participate in Stifel’s 2026 Virtual Immunology and Inflammation Forum”, EQ closed down 9.51% at $1.85 on Sep 16, 2026. The move occurred in the trading session associated with this company update.
Company overview
Immunobiology Company
Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance.
EQ504
EQ504 is a selective aryl hydrocarbon receptor modulator with a multimodal, non-immunosuppressive mechanism designed to support barrier function and regulate tissue inflammation.
Local Delivery Strategy
Potential formulations include targeted gastrointestinal delivery for ulcerative colitis and inhaled delivery for inflammatory lung diseases.
Future catalysts
- Initiation of the Phase 1 proof-of-mechanism study of EQ504 in the fourth quarter of 2026.
- Topline Phase 1 data for EQ504 approximately six months after study initiation.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Equillium, Inc. (EQ)?
Equillium, Inc. (EQ) most recently closed at 1.89 USD, a +1.89% move versus the previous session.
What is the market cap of Equillium, Inc. (EQ)?
Equillium, Inc. currently has a market capitalization of 176M USD on BioPharmSignal.
What does Equillium, Inc. do?
Immunobiology Company Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance. EQ504 EQ504 is a selective aryl hydrocarbon receptor modulator with a multimodal, non-immunosuppressive mechanism designed to support barrier function and regulate tissue inflammation. Local Delivery...
On which exchange is EQ stock listed?
Equillium, Inc. (EQ) is associated with NASDAQ, United States, Biopharma.
What is Immunobiology?
Immunobiology Company Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance.
Which conditions is Equillium, Inc. targeting with Immunobiology?
Equillium, Inc. is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Equillium, Inc. describe recent progress with Immunobiology?
Initiation of the Phase 1 proof-of-mechanism study of EQ504 in the fourth quarter of 2026. Topline Phase 1 data for EQ504 approximately six months after study initiation.
What is Equillium?
Immunobiology Company Equillium develops therapies for severe autoimmune and inflammatory disorders using mechanisms intended to restore immune balance.